Jazz Q1 revenues flat at $898M; GAAP net loss widens to $92.5M; updated guidance after Chimerix

Jazz Pharmaceuticals plc

2025-Q1 EPS reported -$1.52 revenue$897,841,000

GAAP net loss $92.5M ($1.52 loss/share) vs $14.6M loss in 1Q24; adjusted net income $105.2M ($1.68 EPS) vs $178.4M ($2.63).
Xywav revenue $344.8M (+9% YoY), Epidiolex $217.7M (+10% YoY); Xyrem fell 42% to $37.2M.
Affirmed 2025 total revenue guidance $4.15-4.40B; updated to reflect Chimerix acquisition and Xyrem settlements.
Completed Chimerix acquisition in April; added dordaviprone; PDUFA Aug 18, 2025 for recurrent H3 K27M-mutant glioma.
Submitted sNDA for Zepzelca in 1L ES-SCLC maintenance; positive CHMP opinion for zanidatamab in 2L BTC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.